The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein

被引:46
作者
Brandlein, Stephanie
Rauschert, Nicole
Rasche, Leo
Dreykluft, Angela
Hensel, Frank
Conzelmann, Ernst
Mueller-Hermelink, Hans-Konrad
Vollmers, H. Peter [1 ]
机构
[1] Univ Wurzburg, Inst Pathol, D-97080 Wurzburg, Germany
[2] Univ Wurzburg, Dept Physiol Chem 2, D-97080 Wurzburg, Germany
[3] Acceptys Inc, Sparta, NJ USA
关键词
D O I
10.1158/1535-7163.MCT-06-0399
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lipids are essential for normal and malignant cells during growth and differentiation. The turnover is strictly regulated because an uncontrolled uptake and accumulation is cytotoxic and can lead to lipoapoptosis: lipoptosis. The human monoclonal antibody SAM-6 binds to a cell surface receptor on malignant cells and to oxidized low-density lipoprotein (LDL). SAM-6 induces an excess of intracellular lipids, by overfeeding malignant cells with oxidized LDL, via a receptor-mediated endocytosis. The treated cells overaccumulate depots of cholesteryl esters and triglyce-rides. This lipid overaccumulation is tumor specific; nonmalignant cells neither bind the antibody nor harvest lipids after incubation. Because for both forms of apoptosis, the death domain dependent ("extrinsic") and independent ("intrinsic"), the activation of proteases is crucial, we also investigated this pathway in more detail. It was found that shortly after internalization of antibody/oxidized LDL/receptor complex and formation of lipid depots, cytochrome c is released by mitochondria. Followed by this, initiator caspase-8 and caspase-9 and effector caspase-3 and caspase-6 are activated. The mechanism of mitochondrial trigger (e.g., by free fatty acids) is under investigation. However, the present data indicate that the SAM-6 antibody induces an intrinsic-like form of apoptosis by overfeeding malignant cells with lipoproteins.
引用
收藏
页码:326 / 333
页数:8
相关论文
共 52 条
[21]   A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody [J].
Hensel, F ;
Brändlein, S ;
Eck, M ;
Schmidt, K ;
Krenn, V ;
Kloetzer, A ;
Bachi, A ;
Mann, M ;
Müller-Hermelink, HK ;
Vollmers, HP .
LABORATORY INVESTIGATION, 2001, 81 (08) :1097-1108
[22]  
Hensel F, 1999, CANCER RES, V59, P5299
[23]   B-1 cells: the lineage question revisited [J].
Herzenberg, LA .
IMMUNOLOGICAL REVIEWS, 2000, 175 :9-22
[24]   The interface between innate and adaptive immunity [J].
Hoebe, K ;
Janssen, E ;
Beutler, B .
NATURE IMMUNOLOGY, 2004, 5 (10) :971-974
[25]  
JANEWAY CA, 1989, COLD SH Q B, V54, P1
[26]   Innate immune recognition [J].
Janeway, CA ;
Medzhitov, R .
ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :197-216
[27]  
Kang PM, 2000, CIRC RES, V86, P1107
[28]   Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer [J].
Karin, M ;
Lawrence, T ;
Nizet, V .
CELL, 2006, 124 (04) :823-835
[29]  
Kita T, 2001, ANN NY ACAD SCI, V947, P199
[30]   The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis [J].
Kobayashi, K ;
Lopez, LR ;
Shoenfeld, Y ;
Matsuura, E .
AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 :442-454